Q1 ahead of expectations; outlook revised higher
29/04/25 -"Q1 results exceeded consensus, aided by strong performances across focus areas. Consequently, the management raised its full-year outlook. While the firm expects limited US tariff impact in 2025, its ..."
Pages
74
Language
English
Published on
29/04/25
You may also be interested by these reports :
30/04/25
Q1 sales slightly exceeded expectations. While the growth was largely driven by Biosimilars (similar to previous quarters), it was somewhat ...
29/04/25
Q1 profits exceeded the street’s expectations, supported by a healthy performance across segments. However, the management maintained its full-year ...
29/04/25
Q1 results exceeded consensus, aided by strong performances across focus areas. Consequently, the management raised its full-year outlook. While the ...
28/04/25
The Monsanto acquisition continues (8 years down the drain…) to negatively impact investor sentiment, pending the resolution of Bayer’s (Buy; ...